© 2005 European Society of Cardiology
Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study
a Institute of Cardiology, University of Debrecen 4004 Debrecen, P.O.B.: 1, Hungary
b Department of Cardiology, Medical University of Silesia in Katowice Poland
* Corresponding author. Tel./Fax: +36 52 414 928. E-mail address: edes{at}jaguar.unideb.hu
 |
Abstract |
|---|
Aim: To examine the effect of the beta1-selective beta-blocker nebivolol, administered as add-on therapy, on left ventricular function in 260 elderly patients (>65 years) with chronic heart failure (CHF).
Methods: The principal inclusion criteria were (1) NYHA class II–IV CHF and (2) a left ventricular ejection fraction (LVEF) 
35%. The primary end-point was the change in LVEF in response to nebivolol treatment for 8 months.
Results: Baseline LVEF values in the two groups were as follows: nebivolol 25.41±7.09% and control 26.41±5.55%. LVEF improved significantly (p=0.027) more in the nebivolol group (6.51±9.15%) than in the control group (3.97±9.20%), the relative improvement (percentage increase in the initial value) being 35.70±57.62% in the nebivolol group and 19.19±40.96% (p=0.008) in the placebo group. Examination of different subgroups did not reveal any heterogeneity in the effects of nebivolol treatment vs. placebo treatment. There were no significant differences between the nebivolol and placebo groups as concerns the changes in clinical status, quality of life, or safety parameters.
Conclusion: The findings of the ENECA study confirmed that nebivolol significantly improved cardiac function and proved to be safe and well tolerated in elderly patients with signs of CHF and an impaired LVEF.
Key Words: Nebivolol • Chronic heart failure • Ejection fraction • Left ventricular function
Received May 5, 2004; Revised September 1, 2004; Accepted October 18, 2004
Sponsorship: This study was sponsored by the Berlin-Chemie AG, Menarini Group, Berlin, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Maffei and G. Lembo Nitric oxide mechanisms of nebivolol Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 317 - 327. [Abstract] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Gray and U. A. Ndefo Nebivolol: A new antihypertensive agent Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1125 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veverka, D. S Nuzum, and J. L Jolly Nebivolol: A Third-Generation {beta}-Adrenergic Blocker Ann. Pharmacother., July 1, 2006; 40(7): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|